Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / PFE - Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

PFE - Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Pfizer Inc.
  • Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate.
  • The global market opportunity for colorectal cancer is expected to reach $17.8 billion by 2026. About 50% of colorectal cancer population has KRAS mutation.
  • Two other indications being targeted with onvansertib are metastatic pancreatic ductal cancer and Zytiga-resistant metastatic castration-resistant prostate cancer.
  • Onvansertib has great potential because, in preclinical studies, it has shown to synergize well with 12+ targeted/chemotherapies.

For further details see:

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Stock Information
Company Name: Pfizer Inc.
Stock Symbol: PFE
Market: NYSE
Website: pfizer.com
Menu
PFE PFE Quote PFE Short PFE News PFE Articles PFE Message Board
Get PFE Alerts

News, Short Squeeze, Breakout and More Instantly...